21 October 2022 | Other

Immune response from Moderna's updated Omicron vaccine persists for 3 months

Moderna Inc's COVID-19 booster vaccine, aimed at the BA.1 Omicron strain, elicits a powerful immune reaction against this subvariant, keeping antibodies at a high level for at least three months, as reported by the company.

The vaccine developed by Moderna against the Omicron variant has already received regulatory approval in a number of countries.

Stephane Bancel, Chief Executive Officer of Moderna Inc, said that clinical trials have shown an excellent immune response, which has been achieved with the help of a bivalent booster and retains its effect for at least 3 months.

The company also noted that the data regarding the trials of its target vaccine BA.4/BA.5 in humans are expected later this year.

Company MarketCheese
Period: 07.08.2026 Expectation: 650 pips
AUDCAD is poised to approach channel’s upper boundary after testing support
Yesterday at 11:05 AM 45
Period: 31.08.2026 Expectation: 1150 pips
Go long on USDCAD with 1.41250 in sight
Yesterday at 09:42 AM 23
Period: 30.09.2026 Expectation: 2700 pips
Buying GBPUSD up to 1.3600
Yesterday at 09:08 AM 20
Period: 14.08.2026 Expectation: 400 pips
Invest in Brent crude with $88.50 target
Yesterday at 08:38 AM 29
Period: 07.08.2026 Expectation: 770 pips
GBPUSD sharp rally gives way to correction
Yesterday at 06:00 AM 17
Period: 06.08.2026 Expectation: 800 pips
Selling S&P 500 Index with 7,250 target amid rising bearish pressure
30 July 2026 45
Go to forecasts